Please assess the completion status of the following clinical trial:

Trial Title: Ga-68-PSMA-11 in Men With Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to tolerate PET/CT imaging and one or more of the following:~* Patients with newly diagnosed prostate cancer with primary staging classified at high/intermediate risk per NCCN guidelines OR~* Biochemical Recurrence: Patients with rising PSA after definitive therapy with prostatectomy or radiation therapy or other local therapies~Exclusion Criteria:~* Claustrophobia or any other condition that would preclude PET/CT imaging.~* Any constellation of medical conditions that indicate expectancy of less than one year

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ga-68-PSMA-11 PET/CT (Type: EXPERIMENTAL): Administration of Ga-68-PSMA-11 and acquisition of PET/CT

Based on this trial design, predict the completion outcome and termination type (if applicable).